BRKRHealthcare · Medical DevicesThe 14 Wall Street analysts covering Bruker Corp. hold a median 12-month price target of $60 — -2.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 19 Sept 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Bruker Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (89): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (57): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BRKR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −2.3% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | UBS | Maintains | Neutral | $45 → $65 |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 5 Aug 2026 | Citigroup | Maintains | Neutral | $60 → $53 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $44 → $60 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | $60 → $70 |
| 7 July 2026 | Leerink Partners | Maintains | Outperform | — |
| 29 June 2026 | Guggenheim | Maintains | Buy | — |
| 24 June 2026 | Barclays | Maintains | Overweight | — |
| 8 June 2026 | JP Morgan | Maintains | Overweight | — |
| 2 June 2026 | Wolfe Research | Assumes | Peer Perform | — |
| 7 May 2026 | Barclays | Maintains | Overweight | — |
| 7 May 2026 | Citigroup | Maintains | Neutral | — |
| 7 May 2026 | TD Cowen | Maintains | Hold | — |
| 7 May 2026 | UBS | Maintains | Neutral | — |
| 15 Apr 2026 | Barclays | Maintains | Overweight | — |
| 14 Apr 2026 | Barclays | Maintains | Overweight | — |
| 30 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 13 Feb 2026 | Barclays | Maintains | Overweight | — |
| 13 Feb 2026 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BRKR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Bruker Corp. returned +85.5% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 45% of US stocks
Cheaper than 25% of US stocks
Cheaper than 14% of US stocks
Higher than 39% of US stocks
Higher than 42% of US stocks
Higher than 61% of US stocks
Higher than 64% of US stocks
Higher than 27% of US stocks
Higher than 41% of US stocks
Higher than 66% of US stocks
Higher than 6% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bruker Corp. has a market value of $9.4B and an enterprise value of $11.1B.
Revenue in the twelve months to 30 June 2026: $3.5B. The latest quarter grew 5.2% year on year.
Net income over the same four quarters: −$64.5M, a −1.8% net margin.
Diluted earnings per share, trailing twelve months: $−0.70.
Free cash flow in the twelve months to 30 June 2026: $64.5M.
Bruker Corp. spent $54.7M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 74.9×; forward P/E: 25.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.33%, paying out 38% of earnings.
Bruker Corp. employs 11,085 people — $316K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bruker Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bruker Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published by Seeking Alpha.
Why it matters — A Bruker watcher would care because the transcript offers direct insight into management's remarks and strategy as shared with investors at a major healthcare conference.
Bruker Corporation presented at the Wells Fargo 21st Annual Healthcare Conference, with a transcript of the presentation published on Seeking Alpha. The coverage captures the company's remarks at the industry event.
Why it matters — A BRKR watcher would gain insight into the company's positioning and messaging as presented to the investment community at a major healthcare conference.
Bruker Corporation announced that its senior leadership will present at three upcoming investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bank of America Global Healthcare Conference.
Why it matters — BRKR watchers would care because the company's executive presentations at these major healthcare conferences offer opportunities for investors to hear directly from senior leadership about the business.
Bruker Energy & Supercon Technologies (BEST), a segment of Bruker Corporation, and Luvata Materials & Solutions announced a strategic collaboration to support growing demand for superconducting materials and technologies for next-generation magnetic confinement fusion power demonstration plant projects worldwide.
Why it matters — This collaboration positions Bruker's BEST segment to participate in the expanding market for superconducting materials used in fusion power projects, which could be relevant to Bruker's growth opportunities.
Bruker (BRKR) reported earnings 30 days ago and its stock has risen 12.5% since that report. The item discusses what may be next for the company following the earnings release.
Why it matters — The double-digit share price gain since the earnings report signals investor confidence in Bruker's recent financial performance, which BRKR watchers will want to track.
The 14 Wall Street analysts covering Bruker Corp. have a median 12-month price target of $60, with estimates ranging from $40 to $70. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Bruker Corp., 8 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Bruker Corp. 87 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Bruker Corp. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (89 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies -2.3% from the last close, and Ticker Nerd's factor model ranks Bruker Corp. 87 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bruker Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BRKR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $70 over the next 12 months.
Bruker Corp. returned +85.5% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications.
The most recent item we track (Seeking Alpha, 16 Sept 2026): "Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Bruker Corporation presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of its presentation was published by Seeking Alpha.
Bruker Corp. is a scientific instruments and analytical solutions company that provides technologies for life science, materials research, and diagnostic applications. The company develops, manufactures, and distributes high-performance tools used to study matter at microscopic, molecular, and cellular levels, supporting research and testing across academic, clinical, industrial, and government settings. Its product portfolio includes magnetic resonance, mass spectrometry, X-ray, microscopy, metrology, chromatography, and molecular spectroscopy systems, along with specialized diagnostic and microbiology solutions. Bruker serves customers in biopharmaceuticals, in-vitro diagnostics, nanotechnology, semiconductor process control, and applied markets, making it an important supplier of advanced measurement and detection technologies in the global scientific equipment market.
CEO Dr. Frank H. Laukien Ph.D. · 11,085 employees · United States · https://www.bruker.com
